Quest Diagnostics Inc vs Victoria's Secret & Co — how do they compare? Quest Diagnostics Inc trades at $231.66 (market cap $25.48B), while Victoria's Secret & Co trades at $82.76 (market cap $6.91B). The key difference: Quest Diagnostics Inc is far larger — about 3.7× Victoria's Secret & Co's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Victoria's Secret & Co for 34 Days on average.
| DGX | VSXY | |
|---|---|---|
Market Cap | $25.48B | $6.91B |
Volume | 941,866 | 1,346,928 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $99.97 |
52-Week Low | $173.49 | $28.25 |
Typical Hold Time | 56 Days | 34 Days |
Enterprise Value | $31.23B | $9.29B |
Dividend Yield | 1.49% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
Victoria's Secret (VSXY) trades at $81.83, down 4.62% today, but maintains strong technical momentum with a bullish moving average signal. The company shows improving fundamentals with three consecutive quarterly earnings beats and a robust 45.27% ROE. Recent news highlights the fashion show expansion and omnichannel growth strategy driving international sales momentum. Cash flow projections for 2026 show significant improvement to $334M net cash flow, indicating stronger financial health ahead.
The stock presents a compelling opportunity with 60% analyst buy ratings and an $86.80 consensus target offering 6% upside. However, elevated valuation multiples and recent margin pressure require careful monitoring. The company's Path to Potential initiative shows promising traction, but execution risks and competitive retail pressures remain key considerations for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →